Measuring the activity of the ALCAM gene in primary breast tumors could give physicians advanced warning about the likely clinical outcome of the disease. This should help them decide whether to prescribe a more aggressive treatment regimen, such as chemotherapy, much earlier in the diagnostic process.
Dr Judy King and colleagues, from University of South Alabama and University of Wales College of Medicine, compared the expression of the gene for the Activated Leukocyte Cell Adhesion Molecule (ALCAM) in normal breast tissue and tissue samples from primary breast tumors. To do this they counted the number of mRNA transcripts of the ALCAM gene in the different samples.
The researchers found that the ALCAM gene was significantly less active in higher-grade tumors compared to lower-grade tumors, and in tumors with a worse prognosis compared to those with a better prognosis.
"Tumors from patients who died of breast cancer had significantly lower levels of ALCAM transcripts than those with primary tumors but no metastatic disease or local recurrence," write the researchers.
They continue: "The data clearly suggest that decreased ALCAM expression in the primary tumor is of clinical significance in breast cancer, and that reduced expression indicates a more aggressive phenotype and poor prognosis."
They suggest that quantitative PCR, to measure the number of ALCAM transcripts in a tissue sample from a primary breast tumor, could be used to identify these more aggressive tumors at an early stage.
As ALCAM is involved in keeping cells together in a clump, the researchers hypothesize that reduced expression of the gene might allow the tumor cells to separate from one another. This would allow cells to enter the circulation and promote the formation of secondary tumors, which makes the cancer harder to treat.
This press release is based on the following article:
Activated leukocyte cell adhesion molecule in breast cancer: Prognostic indicator
Judy A King, Solomon F Ofori-Acquah, Troy Stevens, Abu-Bakr Al-Mehdi, Oystein Fodstad, and Wen G Jiang
Breast Cancer Research (2004) 6:R478-R487
To be published 28 June 2004
Upon publication this article will be available free of charge according to Breast Cancer Research's Open Access policy at: http://breast-cancer-research.com/content/6/5/R478
Please quote the journal in any stories you write, and link to the article if you are writing for the web.
For further information, please contact one of the authors Dr Judy King by email at jking@usouthal.edu or phone on 251-471-7779.
Alternatively, or for more information about the journal or Open Access publishing, contact Gemma Bradley by phone on 44-207-631-9931 or by email at press@biomedcentral.com
Breast Cancer Research (http://breast-cancer-research.com) is published by BioMed Central (http://www.biomedcentral.com), an independent online publishing house committed to providing Open Access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science. BioMed Central currently publishes over 100 journals across biology and medicine. In addition to open-access original research, BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.
Journal
Breast Cancer Research